CF PharmTech, Inc. Announces HK\$300 Million H Share Placement to Accelerate Global Expansion and Product Pipeline
Key Points for Investors
- Placing of 21.75 million new H Shares under General Mandate at HK\$13.82 per share, representing an 11.97% discount to last closing price.
- Gross proceeds: Approximately HK\$300.55 million; Net proceeds: Approximately HK\$294.81 million.
- Use of Proceeds: 70% for clinical and pre-clinical development of innovative drugs, 15% for complex inhalation formulation products, and 15% for working capital and corporate purposes.
- Shareholder dilution: The placement represents 7.23% of H shares in issue and 5.30% of total shares pre-placement; post-placement, H shares increase to 6.74% and total shares to 5.03%.
- Lock-up period: The Company cannot issue more shares or similar instruments for 90 days after completion, except for certain awards.
- Shareholding structure: Increase in public float from 56.7% to 58.9% post-placement; Company remains compliant with minimum public float requirements.
- Completion Date: Expected August 6, 2026, subject to conditions precedent including regulatory approvals and no material adverse changes.
- No further shareholder approval required for this placement under existing mandate.
- Potential price sensitivity: The significant discount, dilution, use of proceeds, and lock-up are all potentially price-moving information for shareholders.
In-depth Details of the Placement
CF PharmTech, Inc., a commercial-stage pharmaceutical company specializing in inhalation drug delivery, announced a major capital raising initiative through the placement of 21,747,700 new H Shares at a price of HK\$13.82 per share. This price represents a 11.97% discount to the last traded price of HK\$15.70 and a 12.15% discount to the five-day average closing price. The placement is conducted under the existing General Mandate and is not subject to further shareholder approval.
The placement is expected to raise HK\$300.55 million in gross proceeds and HK\$294.81 million in net proceeds after commissions and expenses, with a net issue price of approximately HK\$13.56 per share. The new shares represent 7.23% of H Shares and 5.30% of total shares pre-placement, diluting existing shareholders but also strengthening the company’s capital base for future growth.
Completion of the placement is targeted for August 6, 2026, pending various conditions including listing approval, regulatory clearances from PRC authorities, and absence of material adverse changes or market disruptions. The shares are to be placed with at least six independent, non-connected investors.
Strategic Rationale and Use of Proceeds
The company states that the new funds will accelerate its transformation into a global inhalation drug delivery platform, expand manufacturing capabilities, and advance its innovative product pipeline. Specifically, the proceeds will be used as follows:
- 70% (HK\$206.37 million): Clinical and pre-clinical development of innovative drug candidates, including key Phase I/II trials for ICF004 (idiopathic pulmonary fibrosis), ICF001 (pulmonary hypertension), and pre-clinical programs (CF075 EDS, CF079, CN081, CN064).
- 15% (HK\$44.22 million): Development of complex inhalation formulation products globally, including CMC and clinical studies for CF048, CF059/CF060, CF066 EDS, and others.
- 15% (HK\$44.22 million): Working capital and general corporate purposes, such as R&D personnel recruitment and facility operations.
All proceeds are to be fully utilized by December 31, 2029, and will not replace the planned use of funds from the company’s October 2025 global offering, which remains largely unutilized and reserved for previously disclosed purposes.
Shareholder Impact and Shareholding Structure
Post-placement, the company’s shareholding structure will shift, with total issued shares rising from 411,978,387 to 433,726,087. The public float will increase from 56.7% to 58.9%, and the new shares will be fully fungible with existing H Shares. No single placee is expected to become a substantial shareholder as a result of this placement.
The company has also committed to a 90-day lock-up period following the placement, during which it will not issue, place, or transfer additional equity securities, with limited exceptions for share awards.
Amendments to the articles of association will be made to reflect the new share capital, but no further shareholder approval is required.
Risks and Conditions
Completion of the placement is subject to a number of conditions, including regulatory approvals, no material adverse market or company changes, and successful placement to independent investors. There is a risk that the placement may not proceed if these conditions are not met.
Potential Share Price Implications
- The significant discount to the market price may exert downward pressure on the share price in the short term.
- The strengthening of the balance sheet and acceleration of the company’s strategic plans could support long-term value creation.
- Shareholders should closely monitor the completion of the placement and regulatory filings, as delays or failure to complete may affect sentiment.
Disclaimer
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult their financial advisors before making investment decisions. The completion of the share placement is subject to various conditions and may or may not proceed. Past performance is not indicative of future results.
CF PharmTech, Inc. 發佈 3 億港元 H 股配售 加快全球擴張及產品管線發展
投資者重點
- 配售 2,174.77 萬股新 H 股，每股配售價 13.82 港元，較上日收市價折讓 11.97%。
- 配售所得總額：約 3.0055 億港元；淨額：約 2.9481 億港元。
- 資金用途：70% 用於創新藥物臨床及前期開發，15% 用於全球複雜吸入製劑產品，15% 作營運資金及公司用途。
- 股東攤薄：配售前佔 H 股 7.23%、總股本 5.30%；配售後分別為 6.74% 及 5.03%。
- 禁售期：公司於交割日起 90 天內不得再發行或配售股份（部分獎勵除外）。
- 公眾持股比例：配售後由 56.7% 升至 58.9%，持續符合上市規則要求。
- 預期完成日期：2026 年 8 月 6 日，需符合前置條件包括監管批准及無重大不利變動。
- 無需額外股東批准，已獲一般性授權。
- 敏感信息：配售顯著折讓、股本攤薄、資金用途及禁售安排均具潛在價格影響。
詳情解讀
CF PharmTech, Inc.（賽孚製藥）公佈透過一般性授權，以每股 13.82 港元配售 2,174.77 萬股新 H 股，折讓 11.97%。配售總額約 3.01 億港元，扣除開支後淨額約 2.95 億港元，每股淨集資價約 13.56 港元。
配售股份佔現有 H 股 7.23%、總股本 5.30%；配售後分別為 6.74% 及 5.03%。現有及新股東將出現一定程度攤薄，但公司資本實力獲大幅提升，有助未來發展。
預計於 2026 年 8 月 6 日完成交割，需獲香港聯交所及內地監管機構批准，且無重大負面變動或市場波動。股份將配售予不少於六名獨立第三方投資者，無任何配售對象將因此成為主要股東。
募資用途
- 70%（2.06 億港元）：創新藥物的臨床及前期開發，包括 ICF004（肺纖維化）、ICF001（肺高壓）等多個重點項目及四款前期產品。
- 15%（4,422 萬港元）：全球複雜吸入製劑產品開發，包括 CMC、臨床及器械開發（CF048、CF059/CF060、CF066 EDS 等）。
- 15%（4,422 萬港元）：營運資金及一般公司用途，包括招聘研發人員及設施運營。
所有資金預計於 2029 年 12 月 31 日前全部用完，並不影響 2025 年上市時募資的既定用途。
股東結構影響
配售完成後，公司總股本由 4.12 億股升至 4.34 億股，公眾持股比例由 56.7% 升至 58.9%。新配售股份與現有 H 股完全同權同利。公司承諾配售後 90 天內不會再發行或轉讓股份（獎勵除外），保障市場穩定。
公司亦會根據新資本結構修訂公司章程，無需再經股東批准。
風險提示及條件
配售須取得監管批准，且無重大不利變化，否則可能不會完成。股東應密切關注配售進展及相關監管申報情況。
潛在股價影響
- 配售價大幅折讓，短期內可能對股價構成壓力。
- 資本增強及戰略推進有利長遠增值。
- 配售及監管程序若有延誤或未能完成，或會影響市場情緒。
免責聲明
本文僅供資訊參考，並不構成任何投資建議，亦不建議買賣任何證券。投資者應自行評估風險及諮詢財務顧問。配售能否完成存在不確定性，過往表現不預示未來結果。
